Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Medical Journal of Indonesia Journal of Social Research
Syafruddin A.R. Lelosutan
Unknown Affiliation
Humanities Computer Science & IT Economics, Econometrics & Finance Education Medicine & Pharmacology Social Sciences

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Asthma symptoms improvement in moderate persistent asthma patients with gastroesophageal reflux disease (GERD): the role of proton-pump inhibitor Susanto, Agus D.; Yunus, Faisal; Wiyono, Wiwien H.; Sawitri, Neni; Lelosutan, Syafruddin A.R.
Medical Journal of Indonesia Vol 17, No 3 (2008): July-September
Publisher : Faculty of Medicine Universitas Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (453.731 KB) | DOI: 10.13181/mji.v17i3.317

Abstract

This study aimed to evaluate effect of proton pump inhibitor (esomeprazole) on asthma symptoms, use of inhaled bronchodilator and peak expiratory flow rate (PEFR) in moderate persistent asthma with gastroesofageal refluks disease (GERD). This randomized single blind, controlled clinical trial study was conducted at Persahabatan Hospital, Jakarta from July 2004 until October 2005. Samples were moderate persistent asthma patients with GERD. GERD is diagnosed GERD symptoms and proof of oesophagitis from endoscopy and or histapatologic examination from oesophagus biopsy. Phase 1:2 week run-in period patient received inhaled budesonide 2x200 ug/day. Phase 2: patient randomised to receive inhaled budesonide 2 x 400 ug/day with esomeprazole 40 mg/day or without esomeprazole (control group) for 8 weeks. Phase 3: 4 week wash out period, patient receive inhaled budesonide 2 x 200 ug/day. Diary cards were assessed at run-in periode, after treatment 4 weeks, 8 weeks and wash out. There were 32 patients (23 female and 9 male) completed the study. Mean total asthma symptoms score daily were significantly decreased on esomeprazole vs without esomeprazole after 8 weeks (-2.29 vs -0.90; p < 0.05). Mean use of inhaled bronchodilator was significantly decreased on esomeprazole vs without esomeprazole after 8 weeks (-1.09 vs -0.42; p < 0.05). Morning and evening PEFR improved higher on esomeprazole than without esomeprazol but were not significantly difference. In conclusion, administration esomeprazole 40 mg daily improved asthma symptoms and lower the use of inhaled bronchodilator in moderate persistent asthma patients with GERD. (Med J Indones 2008; 17: 169-74)Keywords: Asthma symptoms, inhaled bronchodilator, moderate persistent asthma, GERD, esomeprazole
Case Report: Severe Persistent Asthma With Acute Exacerbation Raweroz, Vetho; Syaifullah, Muhammad; Lelosutan, Syafruddin A.R.
Journal of Social Research Vol. 4 No. 9 (2025): Journal of Social Research
Publisher : International Journal Labs

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55324/josr.v4i9.2753

Abstract

Introduction: Asthma is a chronic inflammatory disease of the airways characterized by airway hyperresponsiveness to various stimuli, leading to recurrent symptoms such as wheezing, shortness of breath, chest tightness, and coughing, especially at night or in the early morning. Case Report: This paper presents an analysis of a 55 year old man who arrived with worsening shortness of breath that had begun five hours before admission. The patient reported being unable to take deep breaths, described a heavy feeling in the chest, and produced audible wheezing. The dyspnea was accompanied by a productive cough with yellowish sputum that became more severe at night. He could not speak fluently-only in short phrases-felt more comfortable sitting upright, and appeared anxious. Spirometry showed an FVC of 48 % predicted and an FEV? of 41 % predicted. Conclusion: Asthma is a chronic inflammatory airway disease with bronchial hyperresponsiveness, causing episodic, variable, and reversible symptoms (wheezing, dyspnea, cough, chest tightness). Diagnosis is primarily established by spirometry. Stepwise therapy (Steps 1–5) is tailored to severity and control to achieve optimal daily symptom control and prevent exacerbations while using the lowest effective dose.
Co-Authors Agus D. Susanto Faisal Yunus Muhammad Syaifullah, Muhammad Neni Sawitri Raweroz, Vetho Wiwien H. Wiyono